Plains All American Pipeline (PAA)
(Delayed Data from NSDQ)
$17.69 USD
+0.08 (0.45%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $17.68 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
PAA 17.69 +0.08(0.45%)
Will PAA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PAA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PAA
Implied Volatility Surging for Plains All American (PAA) Stock Options
Zacks Industry Outlook Highlights Enterprise Products, Energy Transfer and Plains All American Pipeline
PAA: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Oil & Gas Pipeline Stocks to Watch From a Prospering Industry
Energy Transfer Stock Price Increases 21.8% YTD: How to Play It Now?
Diversified Energy (DEC) to Post 1H24 Earnings: What's in the Cards?
Other News for PAA
Financials For Plains All American Pipeline Remain Strong
A Major Market Reversal Is Likely Coming
PharmAust Limited Announces Corporate Rebranding
PharmAust Limited Advises Investor Caution
PharmAust’s Promising Strides in ALS Treatment